Royalty Pharma plc Class A Ordinary Shares (RPRX) Financial Statements
Historical financial data — 24 statements covering FY2020–FY2025
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma r...
Royalty Pharma plc Class A Ordinary Shares's revenue increased 5.1% year over year, from $2.26B to $2.38B.
Net income decreased 10.2% over the same period, from $859.0M to $770.9M.
Over the 5-year period from FY2020 to FY2025, revenue grew by 12% in total.
Total debt increased by 29.6% to $8.57B.
The debt-to-equity ratio stands at 0.88, indicating a moderate leverage profile.
Operating cash flow declined 10.1% to $2.49B.
Royalty Pharma plc Class A Ordinary Shares maintains a strong net profit margin of 32.4%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2024 | $537.3M-5.4% | $102.0M | $269.6M | $269.6M | $658.2M | $17.66B | $7.60B | $9.75B |
| Q3 FY2024 | $564.7M+5.1% | $544.0M | $735.1M | $735.1M | $703.6M | $18.04B | $6.61B | $10.26B |
| Q4 FY2024 | $593.6M+5.1% | $208.2M | $361.5M | $361.5M | $742.5M | $18.22B | $6.61B | $10.34B |
| Q1 FY2025 | $568.2M-4.3% | $238.3M | $534.2M | $534.2M | $596.1M | $17.61B | $6.62B | $9.79B |
| Q2 FY2025 | $578.7M+1.8% | $30.2M | $209.8M | $209.8M | $364.0M | $18.32B | $7.00B | $9.50B |
| Q3 FY2025 | $609.3M+5.3% | $288.2M | $427.2M | $427.2M | $702.6M | $19.35B | $8.57B | $9.62B |
| Q4 FY2025 | $622.0M+2.1% | $214.2M | $388.4M | $388.4M | $827.1M | $19.62B | $8.57B | $9.71B |
| Q1 FY2026 | $630.6M+1.4% | $294.7M | $563.0M | $563.0M | $718.2M | $19.82B | $8.58B | $9.94B |
Balance Sheet Summary (Latest Period)
Royalty Pharma plc Class A Ordinary Shares (RPRX) Financial Statements & Revenue History
Royalty Pharma plc Class A Ordinary Shares (RPRX) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry trading at $58.27 with a market capitalization of $26. This page provides 24 historical financial statements for Royalty Pharma plc Class A Ordinary Shares, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Royalty Pharma plc Class A Ordinary Shares reported revenue of $2.4 billion, representing 5.1% year-over-year growth. The net profit margin of 32.4% reflects strong profitability. The debt-to-equity ratio of 0.88 reflects moderate leverage.
RPRX Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Royalty Pharma plc Class A Ordinary Shares's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether RPRX is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track RPRX's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Royalty Pharma plc Class A Ordinary Shares converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of RPRX's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use RPRX Financial Data
Investors use Royalty Pharma plc Class A Ordinary Shares's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare RPRX's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how RPRX's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View RPRX's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Royalty Pharma plc Class A Ordinary Shares's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.RPRX trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.